Chronic inflammation in the tumor microenvironment and evasion of the antitumor effector
immune response are two of the emerging hallmarks required for oncogenesis and cancer …

Background Resistance to therapy is a major problem in treating head and neck squamous
cell carcinomas (HNSCC). Complement system inhibition has been shown to reduce tumor …

Advances in understanding the molecular mechanisms of tumor progression have achieved
impressive progress in the treatment of cancer and so-called immune checkpoint inhibitors …

Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance
to therapy and therefore understanding the underlying mechanisms is an urgent challenge …

The complement system consists of a tightly regulated network of proteins that play an
important role in host defense and inflammation. Complement activation results in …

Complement is a part of the innate immune system that contributes to first-line host defense.
It is also implicated in a number of human inflammatory conditions and has attracted interest …

With the awareness that immune-inflammatory cross-talk is at the heart of many disorders,
the desire for novel immunomodulatory strategies in the therapy of such diseases has grown …

The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …

Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …

The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have
examined the role of complement components in the progression of cSCC. Analysis of cSCC …